Evogene (EVGN)

• Market cap: $9.17M
• 1 day: 0.00%
• 5 days: 3.05%
• 1 month: -19.16%
• 3 months: -50.00%
• 6 months: -78.40%
• Year to date: -84.50%
• 1 year: -84.57%
• 5 years: -90.94%
• 10 years: -98.62%

About: Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment followed by Industry.

Employees: 143

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

2.11% more ownership

Funds ownership: 8.18% [Q2] → 10.29% (+2.11%) [Q3]

37% less capital invested

Capital invested by funds: $2.7M [Q2] → $1.7M (-$999K) [Q3]

50% less funds holding

Funds holding: 28 [Q2] → 14 (-14) [Q3]

82% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 17

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 11